Formulation Development

EXCLUSIVE ONLINE CONTENT

1/25/2022

Biomea Fusion Announces First Patient Dosed

Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….